Richard BETHELL, PhD, MA (he/him/his)

Sulis Therapeutics
Stockholm, Sweden

>30 years of drug discovery and development experience in large and small biopharma companies, including major contributions to two approved drugs.

Presentation(s):

• 0929: SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1^-/- mice

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): GlaxoSmithKlein(GSK): Equity interest (Ongoing)